Merck Keytruda Combos Strengthen Oncology Platform And Raise Patent Questions [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) reported multiple positive Phase 3 results for KEYTRUDA-based combinations in renal cell carcinoma, bladder cancer, and ovarian cancer. The trials showed significant survival benefits in adjuvant and advanced renal cell carcinoma, muscle-invasive bladder cancer, and platinum-resistant recurrent ovarian cancer. These data have already translated into U.S. and European regulatory approvals and priority review acceptances. For investors watching Merck, the latest KEYTRUDA updates come as the stock trades around $123.82, with a 1 year return of 39.3% and a 5 year return of 108.1%. The company's oncology franchise remains central to its story, and these late-stage results reinforce how important KEYTRUDA combinations are to Merck's current profile. Looking ahead, the breadth of trial readouts and rapid movement into regula
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Assessing Merck (MRK) Valuation As Recent Share Price Strength Meets Conflicting Fair Value Views [Yahoo! Finance]Yahoo! Finance
- Merck's KEYTRUDA Combo Wins and Pipeline Shuffle Might Change The Case For Investing In Merck (MRK) [Yahoo! Finance]Yahoo! Finance
- ???????:???????????2035????411.8?????????? ? ???????????????? [CNET News]CNET News
- Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead? [Yahoo! Finance]Yahoo! Finance
- Big Pharma's next entrant could come from China [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- 2/13/26 - Form 144/A
- MRK's page on the SEC website